|
Pneumococcal vaccine – Prevenar 13
|
| bet | 483/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Pneumococcal vaccine – Prevenar 13
Revision Date : 2-3-2020
|
Approved : TC, KOH
|
Alert
|
Increased risk of fever when pneumococcal conjugate vaccine concurrently administered with other vaccines.
Register the vaccination with the National Immunisation Registry by faxing a copy of the immunisation details from “My personal health record” to Anne Allen on 93824309.
|
Indication
|
1. Primary immunisation against pneumococcal disease in infants at 6 weeks/2 months, 4 and 6 months of age.
2. Booster dose at 12 months in at risk children:
Indigenous children in Northern Territory, Queensland, South Australia or Western Australia.
Children with a medical condition associated with an increased risk of invasive pneumococcal disease.
Preterm infants < 28 weeks gestation
3. Catch-up vaccination schedules in children up to 5 years of age.
|
Action
|
Induces the production of antibodies against Streptococcus pneumoniae.
|
Drug Type
|
Vaccine
Conjugated pneumococcal vaccine composed of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F each conjugated to CRM197 carrier protein.
|
|
|
| |
